% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Group:277888,
      author       = {S. W. Group},
      collaboration = {the ESC Cardiovascular {Risk Collaboration}},
      othercontributors = {L. Pennells and S. Kaptoge and H. B. Østergaard and S. H.
                          Read and F. Carinci and J. Franch-Nadal and C. Petitjean and
                          O. Taylor and S. H. J. Hageman and Z. Xu and F. Shi and S.
                          Spackman and S. Gualdi and N. Holman and R. B. Da
                          Providencia E Costa and F. Bonnet and H. Brenner$^*$ and R.
                          F. Gillum and S. Kiechl and D. A. Lawlor and L. Potier and
                          B. Schöttker$^*$ and R. Sofat and H. Völzke and J. Willeit
                          and Z. Baltane and S. Fava and S. Janos and A. Lavens and S.
                          Pildava and T. Poljicanin and I. Pristas and P. Rossing and
                          R. Sascha and C. Scheidt-Nave and I. Stotl and G. Tibor and
                          V. Urbančič-Rovan and A.-S. Vanherwegen and D. Vistisen
                          and Y. Du and M. R. Walker and P. Willeit and B. Ference and
                          D. De Bacquer and M. Halle and R. Huculeci and J. W. McEvoy
                          and A. Timmis and P. Vardas and J. A. N. Dorresteijn and I.
                          Graham and A. Wood and B. Eliasson and W. Herrington and J.
                          Danesh and D. Mauricio and M. M. Benedetti and N. Sattar and
                          F. L. J. Visseren and S. Wild and E. Di Angelantonio and B.
                          Balkau and F. Bonnet and F. Fumeron and H. Stocker and B.
                          Holleczek and S. Schipf and C. O. Schmidt and M. Dörr and
                          H. Tilg and C. Leitner and M. Notdurfter and J. Taylor and
                          C. Dale and D. Prieto-Merino and R. F. Gillum and A. Lavens
                          and A.-S. Vanherwegen and T. Poljicanin and I. Pristas and
                          T. Buble and P. Ivanko and P. Rossing and B. Carstensen and
                          C. Heidemann and Y. Du and C. Scheidt-Nave and T. Gall and
                          J. Sandor and Z. Baltane and S. Pildava and J. Lepiksone and
                          C. J. Magri and J. Azzopardi and I. Stotl and J. Real and B.
                          Vlacho and M. Mata-Cases},
      title        = {{SCORE}2-{D}iabetes: 10-year cardiovascular risk estimation
                      in type 2 diabetes in {E}urope.},
      journal      = {European heart journal},
      volume       = {44},
      number       = {28},
      issn         = {0195-668X},
      address      = {Oxford},
      publisher    = {Oxford University Press},
      reportid     = {DKFZ-2023-01555},
      pages        = {2544 - 2556},
      year         = {2023},
      abstract     = {To develop and validate a recalibrated prediction model
                      (SCORE2-Diabetes) to estimate the 10-year risk of
                      cardiovascular disease (CVD) in individuals with type 2
                      diabetes in Europe.SCORE2-Diabetes was developed by
                      extending SCORE2 algorithms using individual-participant
                      data from four large-scale datasets comprising 229 460
                      participants (43 706 CVD events) with type 2 diabetes and
                      without previous CVD. Sex-specific competing risk-adjusted
                      models were used including conventional risk factors (i.e.
                      age, smoking, systolic blood pressure, total, and
                      HDL-cholesterol), as well as diabetes-related variables
                      (i.e. age at diabetes diagnosis, glycated haemoglobin
                      [HbA1c] and creatinine-based estimated glomerular filtration
                      rate [eGFR]). Models were recalibrated to CVD incidence in
                      four European risk regions. External validation included 217
                      036 further individuals (38 602 CVD events), and showed good
                      discrimination, and improvement over SCORE2 (C-index change
                      from 0.009 to 0.031). Regional calibration was satisfactory.
                      SCORE2-Diabetes risk predictions varied several-fold,
                      depending on individuals' levels of diabetes-related
                      factors. For example, in the moderate-risk region, the
                      estimated 10-year CVD risk was $11\%$ for a 60-year-old man,
                      non-smoker, with type 2 diabetes, average conventional risk
                      factors, HbA1c of 50 mmol/mol, eGFR of 90 mL/min/1.73 m2,
                      and age at diabetes diagnosis of 60 years. By contrast, the
                      estimated risk was $17\%$ in a similar man, with HbA1c of 70
                      mmol/mol, eGFR of 60 mL/min/1.73 m2, and age at diabetes
                      diagnosis of 50 years. For a woman with the same
                      characteristics, the risk was $8\%$ and $13\%,$
                      respectively.SCORE2-Diabetes, a new algorithm developed,
                      calibrated, and validated to predict 10-year risk of CVD in
                      individuals with type 2 diabetes, enhances identification of
                      individuals at higher risk of developing CVD across Europe.},
      keywords     = {Male / Female / Humans / Middle Aged / Diabetes Mellitus,
                      Type 2: complications / Diabetes Mellitus, Type 2:
                      epidemiology / Cardiovascular Diseases: epidemiology /
                      Cardiovascular Diseases: etiology / Risk Factors / Glycated
                      Hemoglobin / Europe: epidemiology / Heart Disease Risk
                      Factors / Cardiovascular diseases (Other) / Diabetes (Other)
                      / Prediction model (Other) / Glycated Hemoglobin (NLM
                      Chemicals)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37247330},
      pmc          = {pmc:PMC10361012},
      doi          = {10.1093/eurheartj/ehad260},
      url          = {https://inrepo02.dkfz.de/record/277888},
}